CHARLOTTE, North Carolina (GenomeWeb) – At the Association for Molecular Pathology here this week, Thermo Fisher Scientific announced a new research panel for profiling gene expression in tumors and their surrounding microenvironment, which it hopes has the potential to predict response to cancer immunotherapies with more sensitivity than current assays.

The new offering, called the Oncomine Immune Response Research Assay, enables targeted sequencing of 396 gene transcripts using Ion Torrent next-generation sequencing platforms, with low sample input requirements.